Christina Kraus, MD
Dermatology · Tustin, CANPI 1225491293
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,248 of the $11,422 with a category attached, or 98.5%. LEO Pharma AS accounts for 98.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $8,288, more than ten times the $174 reported in 2022.
Across 6 payments — averaging $1903.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LEO Pharma AS$11K
- Boehringer Ingelheim$94
- TELA Bio, Inc.$80
Across 28 payments — averaging $3656.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$102K
What the payments were for
- Consulting fees$11,24898%
- Food & beverage$1742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LEO Pharma AS | 4 | $11,248 |
| Boehringer Ingelheim | 1 | $94 |
| TELA Bio, Inc. | 1 | $80 |
How this compares
$11,422 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 17 | $338,677 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 38 | $262,596 |
| Dupixent PenDupilumab | 45 | $156,601 |
| OtezlaApremilast | 13 | $59,944 |
| Dupixent SyringeDupilumab | 17 | $57,399 |
| Estradiol | 91 | $7,445 |
| Clobetasol Propionate | 139 | $6,273 |
| Tacrolimus | 22 | $3,093 |
| Fluorouracil | 38 | $2,581 |
| Fluocinonide | 39 | $1,818 |
| Minoxidil | 131 | $1,793 |
| Ketoconazole | 101 | $1,571 |
| MethotrexateMethotrexate Sodium | 56 | $1,400 |
| Tretinoin | 13 | $1,270 |
| Dutasteride | 22 | $1,195 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Tustin
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.